Follow this organization
[ via
] [?]
Children's Hospital Boston
The mission of the Technology and Innovation Development Office (TIDO) is to translate the laboratory and clinical research excellence of Children’s Hospital Boston into products for the public benefit. TIDO uses a multi-faceted approach to promote, support and develop research, technology and clinical innovations through the protection and licensing of intellectual property, investing in Children’s Hospital technologies, and establishing strong research and development partnerships with industry throughout the innovation to product life cycle.
Innovations (127):
- Fibromodulin for the treatment of age related macular degeneration (09 JAN 12)
- miRNA-135a to detect and reverse taxane resistance in tumor cells (07 JAN 12)
- Device for exhaled gas monitoring during high frequency ventilation (19 DEC 11)
- Lodamin for treating uveitis and other autoimmune diseases (09 DEC 11)
- Collagen XXIII: A novel biomarker for non-small cell lung cancer and prostate cancer (08 DEC 11)
- Specific and sensitive diagnostic markers of Kawasaki disease (14 NOV 11)
- MedWatcher: participatory drug safety epidemiology (10 NOV 11)
- Multiple Antigen Presentation System, MAPS (07 NOV 11)
- Stimulating Axon Regeneration by Blocking EGF Receptor Activity (02 OCT 11)
- Assay to Detect Hepcidin (31 AUG 11)
Communities (0):
Children's Hospital Boston isn't a member of any communities.
|
|
Institute Administrator Innovations (0) |
|---|
ProfileFind more innovations
